Abstract
In patients with low-intermediate risk Acute Promyelocytic Leukemia (APL), hemoglobin (HGB) levels below 65g/L at diagnosis were identified as independent risk factors for early death. Despite this risk, remission can still be achieved using low-dose arsenic trioxide (ATO) without extending the required treatment time. Significant differences in clinical characteristics were observed between low-risk and intermediate-risk APL groups, with the intermediate-risk group exhibiting a markedly higher early mortality risk.
Introduction
Acute Promyelocytic Leukemia (APL) has transitioned from a highly fatal disease to one of the most curable forms of leukemia, thanks to the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Ten-year survival rates now frequently exceed 90%. However, a "dark window" persists: the first 30 days of treatment. During this induction phase, early death rates can reach up to 29% in real-world settings, often due to intracranial hemorrhage, infection, or differentiation syndrome (DS).
While much research focuses on high-risk patients (those with white blood cell counts > 10 × 10⁹/L), this study investigates why patients classified as low-to-intermediate risk still face significant early mortality. Identifying specific clinical "red flags" is essential for improving outcomes in these theoretically more salvageable patients.
Methods and Data
This retrospective study analyzed 60 newly diagnosed low-to-intermediate risk APL patients treated at Mianyang Central Hospital between 2013 and 2021. Patients were stratified using the Sanz criteria:
- Low-risk: WBC ≤ 10 × 10⁹/L and platelets > 40 × 10⁹/L.
- Intermediate-risk: WBC ≤ 10 × 10⁹/L and platelets ≤ 40 × 10⁹/L.
The cohort included 14 low-risk and 46 intermediate-risk patients. All received a standard induction regimen of oral ATRA combined with ATO (0.11–0.16 mg/kg/day). Statistical analyses, including univariate tests and multivariate logistic regression, were used to identify independent risk factors for early death.
Key Results and Clinical Insights
Predictors of Early Death
The study found an overall early death rate of 23.3% (14/60). A critical finding was that Hemoglobin (HGB) < 65g/L at diagnosis is a powerful independent predictor of early death (OR = 38.474). This suggests that severe anemia at presentation serves as a marker for a more aggressive disease state requiring intensive supportive care.
Other factors associated with higher mortality in univariate analysis included male gender, lack of combination chemotherapy, and higher WBC counts on the third day of treatment. The primary causes of early death were evenly distributed among hemorrhage (35.7%), severe infection (35.7%), and differentiation syndrome (28.6%).
Survival Disparity Between Risk Groups
A stark contrast was observed between the two risk categories. The 5-year overall survival (OS) rate for the low-risk group was 100%, whereas it was only 69.6% for the intermediate-risk group ($P = 0.025$). Intermediate-risk patients also showed higher lactate dehydrogenase (LDH) levels and higher WBC counts during the early stages of treatment.
Efficacy of Low-Dose ATO
Importantly, the use of low-dose ATO did not negatively impact the time to complete remission (CR). In the survival group, 100% of patients achieved CR, with a median time of approximately 25.87 days. This supports the clinical utility of low-dose ATO in balancing efficacy with reduced toxicity.
Discussion and Limitations
The study highlights that even within the "low-to-intermediate" risk bracket, significant heterogeneity exists. The intermediate-risk group requires more vigilant monitoring and potentially more aggressive early intervention.
However, the study's limitations include a relatively small sample size (n=60), which led to wide confidence intervals for some risk factors. Additionally, the single-center, retrospective design may introduce selection bias. Future multi-center prospective studies are needed to validate HGB as a standard risk stratification metric and to further refine treatment protocols for intermediate-risk APL patients.
Summary updated